725 related articles for article (PubMed ID: 15510160)
1. Post-translational modification of p53 in tumorigenesis.
Bode AM; Dong Z
Nat Rev Cancer; 2004 Oct; 4(10):793-805. PubMed ID: 15510160
[TBL] [Abstract][Full Text] [Related]
2. Promyelocytic leukemia protein is required for gain of function by mutant p53.
Haupt S; di Agostino S; Mizrahi I; Alsheich-Bartok O; Voorhoeve M; Damalas A; Blandino G; Haupt Y
Cancer Res; 2009 Jun; 69(11):4818-26. PubMed ID: 19487292
[TBL] [Abstract][Full Text] [Related]
3. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2.
Hofmann TG; Möller A; Sirma H; Zentgraf H; Taya Y; Dröge W; Will H; Schmitz ML
Nat Cell Biol; 2002 Jan; 4(1):1-10. PubMed ID: 11740489
[TBL] [Abstract][Full Text] [Related]
4. Regulation of p53 responses by post-translational modifications.
Xu Y
Cell Death Differ; 2003 Apr; 10(4):400-3. PubMed ID: 12719715
[No Abstract] [Full Text] [Related]
5. The ARF/oncogene pathway activates p53 acetylation within the DNA binding domain.
Mellert H; Sykes SM; Murphy ME; McMahon SB
Cell Cycle; 2007 Jun; 6(11):1304-6. PubMed ID: 17534149
[TBL] [Abstract][Full Text] [Related]
6. PML regulates p53 stability by sequestering Mdm2 to the nucleolus.
Bernardi R; Scaglioni PP; Bergmann S; Horn HF; Vousden KH; Pandolfi PP
Nat Cell Biol; 2004 Jul; 6(7):665-72. PubMed ID: 15195100
[TBL] [Abstract][Full Text] [Related]
7. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras.
Pearson M; Carbone R; Sebastiani C; Cioce M; Fagioli M; Saito S; Higashimoto Y; Appella E; Minucci S; Pandolfi PP; Pelicci PG
Nature; 2000 Jul; 406(6792):207-10. PubMed ID: 10910364
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells.
Herzer K; Weyer S; Krammer PH; Galle PR; Hofmann TG
Cancer Res; 2005 Dec; 65(23):10830-7. PubMed ID: 16322229
[TBL] [Abstract][Full Text] [Related]
9. PML interaction with p53 and its role in apoptosis and replicative senescence.
Pearson M; Pelicci PG
Oncogene; 2001 Oct; 20(49):7250-6. PubMed ID: 11704853
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation.
Brooks CL; Gu W
Curr Opin Cell Biol; 2003 Apr; 15(2):164-71. PubMed ID: 12648672
[TBL] [Abstract][Full Text] [Related]
11. [Regulation of p53 function and promoter selectivity by post-translational modifications].
Tanaka T
Seikagaku; 2010 Mar; 82(3):200-9. PubMed ID: 20408452
[No Abstract] [Full Text] [Related]
12. Activation and activities of the p53 tumour suppressor protein.
Bálint E E; Vousden KH
Br J Cancer; 2001 Dec; 85(12):1813-23. PubMed ID: 11747320
[TBL] [Abstract][Full Text] [Related]
13. p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3.
Lin J; Tang H; Jin X; Jia G; Hsieh JT
Oncogene; 2002 May; 21(19):3082-8. PubMed ID: 12082540
[TBL] [Abstract][Full Text] [Related]
14. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?
Olsson A; Manzl C; Strasser A; Villunger A
Cell Death Differ; 2007 Sep; 14(9):1561-75. PubMed ID: 17627286
[TBL] [Abstract][Full Text] [Related]
15. Posttranslational modifications involved in the DNA damage response.
Anderson CW; Appella E; Sakaguchi K
J Protein Chem; 1998 Aug; 17(6):527. PubMed ID: 9723732
[No Abstract] [Full Text] [Related]
16. Direct transcriptional activation of promyelocytic leukemia protein by IFN regulatory factor 3 induces the p53-dependent growth inhibition of cancer cells.
Kim TK; Lee JS; Oh SY; Jin X; Choi YJ; Lee TH; Lee Eh; Choi YK; You S; Chung YG; Lee JB; DePinho RA; Chin L; Kim H
Cancer Res; 2007 Dec; 67(23):11133-40. PubMed ID: 18056437
[TBL] [Abstract][Full Text] [Related]
17. The function of PML in p53-dependent apoptosis.
Guo A; Salomoni P; Luo J; Shih A; Zhong S; Gu W; Pandolfi PP
Nat Cell Biol; 2000 Oct; 2(10):730-6. PubMed ID: 11025664
[TBL] [Abstract][Full Text] [Related]
18. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor.
Insinga A; Monestiroli S; Ronzoni S; Carbone R; Pearson M; Pruneri G; Viale G; Appella E; Pelicci P; Minucci S
EMBO J; 2004 Mar; 23(5):1144-54. PubMed ID: 14976551
[TBL] [Abstract][Full Text] [Related]
19. Distinct pattern of p53 phosphorylation in human tumors.
Minamoto T; Buschmann T; Habelhah H; Matusevich E; Tahara H; Boerresen-Dale AL; Harris C; Sidransky D; Ronai Z
Oncogene; 2001 Jun; 20(26):3341-7. PubMed ID: 11423984
[TBL] [Abstract][Full Text] [Related]
20. hADA3 is required for p53 activity.
Wang T; Kobayashi T; Takimoto R; Denes AE; Snyder EL; el-Deiry WS; Brachmann RK
EMBO J; 2001 Nov; 20(22):6404-13. PubMed ID: 11707411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
